SEARCH

SEARCH BY CITATION

References

  • 1
    Gaffey MJ, Iezzoni JC, Weiss LM. Clonal analysis of focal nodular hyperplasia of the liver. Am J Pathol 1996; 148: 10891096.
  • 2
    Paradis V, Laurent A, Fléjou JF, Vidaud M, Bedossa P. Evidence for the polyclonal nature of focal nodular hyperplasia of the liver by the study of X chromosome inactivation. HEPATOLOGY 1997; 26: 891895.
  • 3
    Paradis V, Bièche I, Dargère D, Laurendeau I, Nectoux J, Degott C, et al. A quantitative gene expression study suggests a role for angiopoietins in focal nodular hyperplasia. Gastroenterology 2003; 124: 651659.
  • 4
    Paradis V, Benzekri A, Dargère D, Bièche I, Laurendeau I, Vilgrain V, et al. Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. Gastroenterology 2004; 126: 13231329.
  • 5
    Bioulac-Sage P, Rebouissou S, Sa Cunha A, Jeannot E, Lepreux S, Blanc JF, et al. Clinical, morphological, and molecular features defining so-called telangiectatic focal nodular hyperplasia of the liver. Gastroenterology 2005; 128: 12111218.
  • 6
    Zucman-Rossi J, Jeannot E, Nhieu JT, Scoazec JY, Guettier C, Rebouissou S, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. HEPATOLOGY 2006; 43: 515524.
  • 7
    Goodman ZD. Benign tumors of the liver. In: OkudaK, IshakKG, eds. Neoplasms of the Liver. Tokyo: Springer-Verlag; 1987: 105125.
  • 8
    Wanless IR, Albrecht S, Bilbao J. Multiple focal nodular hyperplasia of the liver associated with vascular malformations of various organs and neoplasia of the brain. Modern Pathol 1989; 2: 456462.
  • 9
    Nguyen BN, Fléjou JF, Terris B, Belghiti J, Degott C. Focal nodular hyperplasia of the liver. A comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol 1999; 23: 14411454.
  • 10
    Attal P, Vigrain V, Brancatelli G, Paradis V, Terris B, Belghiti J, et al. Telangiectatic focal nodular hyperplasia: US, CT, and MR imaging findings with histopathologic correlation in 13 cases. Radiology 2003; 228: 465472.
  • 11
    Zucman-Rossi J, Blanc JF, Sa Cunha A, Jeannot E, Couchy G, Rullier A, et al. β-catenin mutated hepatocellular adenomas (HCA) [Abstract]. HEPATOLOGY 2007; 44(suppl): 155A.
  • 12
    Edmonson HA, Henderson B, Benton B. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med 1976; 294: 470472.
  • 13
    Rooks JB, Ory HW, Ishak KG, Strauss LT, Greenspan JR, Hill AP, et al. Epidemiology of hepatocellular adenoma. JAMA 1979; 242: 644648.
  • 14
    Calle EE, Rodriguez C, Walker-Thurmond KW, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. New Engl J Med 2003; 348: 16251638.
  • 15
    Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 2004; 127: S97103.
  • 16
    Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H, Vaxillaire M, et al. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 1996; 384: 455458.
  • 17
    Bluteau O, Jeannot E, Bioulac-Sage P, Marques JM, Blanc JF, Bui H, et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet 2002; 32: 312315.
  • 18
    Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280: 745751.
  • 19
    Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 1995; 95: 24092415.
  • 20
    Ridker PM, Wilson PWF, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109: 28182825.
  • 21
    Chen YW, Jeng YM, Yeh SH, Chen PJ. P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. HEPATOLOGY 2002; 36: 927935.